A new analysis is offering a potentially significant shift in how doctors approach preventing heart attacks and strokes in people with diabetes. Research presented at the American College of Cardiology’s Annual Scientific Session (ACC.26) suggests that the cholesterol-lowering drug evolocumab can substantially reduce the risk of major cardiac events – by nearly one-third – even in patients who haven’t yet shown signs of significant plaque buildup in their arteries. This finding challenges conventional wisdom that typically reserves such aggressive treatments for those with established heart disease.
For years, the focus has been on secondary prevention – treating patients *after* a cardiac event has occurred. But this study, a detailed glance at data from the larger VESALIUS-CV trial, indicates a benefit for what’s known as primary prevention, intervening *before* a first heart attack or stroke. The implications could be far-reaching, potentially expanding the number of individuals who could benefit from this type of intensive cholesterol management. Understanding the role of the American College of Cardiology in disseminating these findings is crucial for healthcare professionals.
Evolocumab belongs to a class of drugs called PCSK9 inhibitors. These medications operate by boosting the liver’s ability to remove “bad” cholesterol – low-density lipoprotein cholesterol, or LDL-C – from the bloodstream. High LDL-C is a major contributor to the formation of atherosclerosis, the process where plaque accumulates inside arteries, narrowing them and increasing the risk of blockages. The VESALIUS-CV trial initially enrolled 12,257 participants with either existing atherosclerosis or diabetes, all with LDL-C levels of 90 mg/dL or higher, and none of whom had previously experienced a heart attack or stroke. The latest analysis focused on a subset of 3,655 patients *without* known significant atherosclerosis who too had diabetes.
A Paradigm Shift in Cardiovascular Prevention?
The lead author of the study, Nicholas Marston, MD, MPH, a cardiologist and assistant professor of medicine at Brigham and Women’s Hospital and Harvard Medical School in Boston, believes the findings represent a turning point. “I reckon this study changes the paradigm,” he stated. “In current practice, PCSK9 inhibitors are largely reserved for patients who have had a prior heart attack or stroke, but here we see a benefit of using evolocumab not only to treat patients without a history of heart attack or stroke, but without known significant atherosclerosis. It’s a message to physicians and patients that we don’t have to wait until someone has atherosclerosis to treat them intensively. People can—and should—be much more proactive.”
Over a median follow-up period of 4.8 years, researchers found that patients receiving evolocumab experienced a 31% lower rate of major adverse cardiac events – a composite of death from coronary heart disease, heart attack, or ischemic stroke – compared to those receiving a placebo. This benefit became apparent within the first year and grew to around 40% after that initial period. The study also examined a second composite endpoint, including the necessitate for procedures like angioplasty or bypass surgery to open blocked arteries, and saw a similar 31% reduction in risk with evolocumab.
Impact on LDL-C Levels and Overall Mortality
The study also demonstrated a substantial reduction in LDL-C levels among those treated with evolocumab. For patients whose lipid levels were monitored throughout the study (approximately 550 participants), LDL-C dropped to a median of 52 mg/dL at 48 weeks and 44 mg/dL at 96 weeks, compared to 111 mg/dL and 105 mg/dL in the placebo group. While not statistically significant, the evolocumab group also showed a trend toward lower rates of both cardiovascular and all-cause mortality – 32% and 24% reductions, respectively.
These findings align with recent updates to clinical guidelines. The ACC/AHA Guideline on the Management of Dyslipidemia, released earlier this month, emphasizes the importance of lowering LDL-C levels earlier in life and provides more specific treatment goals. “The results from this subgroup analysis strongly support that in these lower-risk patients we should be targeting even lower LDL-C goals that are typically reserved for very high-risk secondary prevention patients,” Marston explained.
Study Limitations and Future Directions
Researchers acknowledge some limitations to the study. It’s possible that some participants in the analysis had undiagnosed atherosclerosis, as coronary imaging wasn’t a requirement for enrollment. This reflects real-world clinical practice, where routine screening for atherosclerosis isn’t typically performed. The study population was primarily older adults (median age 65) and predominantly White (93%), limiting the generalizability of the findings to younger individuals or those from different ethnic backgrounds. Additional research is needed to determine if evolocumab offers similar benefits to these groups.
The VESALIUS-CV trial was funded by Amgen, the manufacturer of evolocumab. The full study was simultaneously published in JAMA at the time of presentation. Marston is scheduled to present the findings in detail on Saturday, March 28, at the ACC.26 conference.
The potential for earlier, more aggressive intervention with medications like evolocumab represents a significant step forward in the fight against cardiovascular disease, particularly for individuals with diabetes who are already at increased risk. However, the decision to initiate such treatment should be made on a case-by-case basis, considering individual risk factors, potential benefits, and the possibility of side effects.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
What do you think about these new findings? Share your thoughts in the comments below, and please share this article with anyone who might locate it helpful.
